Registration Strip Icon for smarter Trade smarter, not harder: Unleash your inner pro with our toolkit and live discussions.

RARE

Ultragenyx Pharmaceutical (RARE)

Ultragenyx Pharmaceutical Inc
Date:
Sort by:
 Showing the most relevant articles for your search:NASDAQ:RARE
DateTimeSourceHeadlineSymbolCompany
07/19/20244:05PMGlobeNewswire Inc.Ultragenyx Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)NASDAQ:RAREUltragenyx Pharmaceutical Inc
07/17/20244:06PMEdgar (US Regulatory)Form 8-K - Current reportNASDAQ:RAREUltragenyx Pharmaceutical Inc
07/17/20244:05PMGlobeNewswire Inc.Ultragenyx Announces Successful End-of-Phase 2 Meeting with FDA for GTX-102 Angelman Syndrome ProgramNASDAQ:RAREUltragenyx Pharmaceutical Inc
07/12/20244:04PMEdgar (US Regulatory)Form S-8 - Securities to be offered to employees in employee benefit plansNASDAQ:RAREUltragenyx Pharmaceutical Inc
06/20/20244:30PMGlobeNewswire Inc.Ultragenyx Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)NASDAQ:RAREUltragenyx Pharmaceutical Inc
06/20/20242:23PMEdgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:RAREUltragenyx Pharmaceutical Inc
06/20/20242:22PMEdgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:RAREUltragenyx Pharmaceutical Inc
06/20/20242:22PMEdgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:RAREUltragenyx Pharmaceutical Inc
06/17/20246:31AMEdgar (US Regulatory)Form 8-K - Current reportNASDAQ:RAREUltragenyx Pharmaceutical Inc
06/14/20245:11PMEdgar (US Regulatory)Form 424B5 - Prospectus [Rule 424(b)(5)]NASDAQ:RAREUltragenyx Pharmaceutical Inc
06/13/20248:49PMGlobeNewswire Inc.Ultragenyx Announces Pricing of Public Offering of Common Stock and Pre-Funded WarrantsNASDAQ:RAREUltragenyx Pharmaceutical Inc
06/12/20247:47PMEdgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:RAREUltragenyx Pharmaceutical Inc
06/12/20245:20PMEdgar (US Regulatory)Form 424B5 - Prospectus [Rule 424(b)(5)]NASDAQ:RAREUltragenyx Pharmaceutical Inc
06/12/20245:10PMEdgar (US Regulatory)Form 144 - Report of proposed sale of securitiesNASDAQ:RAREUltragenyx Pharmaceutical Inc
06/12/20244:05PMGlobeNewswire Inc.Ultragenyx Announces Proposed Public Offering of Common Stock and Pre-Funded WarrantsNASDAQ:RAREUltragenyx Pharmaceutical Inc
06/12/20244:04PMEdgar (US Regulatory)Form 8-K - Current reportNASDAQ:RAREUltragenyx Pharmaceutical Inc
06/12/20244:00PMGlobeNewswire Inc.Ultragenyx Announces Plans to File for Accelerated Approval of UX111 for the Treatment of Sanfilippo Syndrome Type A (MPS IIIA)NASDAQ:RAREUltragenyx Pharmaceutical Inc
06/11/20245:47PMGlobeNewswire Inc.Ultragenyx and Mereo BioPharma Announce New Phase 2 Data from Phase 2/3 Orbit Study Demonstrating Sustained Reductions in Fracture Rates Following Treatment with Setrusumab (UX143) in Patients with Osteogenesis Imperfecta (OI)NASDAQ:RAREUltragenyx Pharmaceutical Inc
06/10/20247:58PMEdgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:RAREUltragenyx Pharmaceutical Inc
06/10/20245:20PMEdgar (US Regulatory)Form 144 - Report of proposed sale of securitiesNASDAQ:RAREUltragenyx Pharmaceutical Inc
06/04/20244:05PMGlobeNewswire Inc.Ultragenyx to Participate at Goldman Sachs 45th Annual Global Healthcare ConferenceNASDAQ:RAREUltragenyx Pharmaceutical Inc
05/30/20244:04PMEdgar (US Regulatory)Form 8-K - Current reportNASDAQ:RAREUltragenyx Pharmaceutical Inc
05/30/20244:00PMGlobeNewswire Inc.Ultragenyx Announces Positive Top-Line Results from Phase 3 Study of DTX401 Gene Therapy for Glycogen Storage Disease Type Ia (GSDIa)NASDAQ:RAREUltragenyx Pharmaceutical Inc
05/17/20244:30PMGlobeNewswire Inc.Ultragenyx Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)NASDAQ:RAREUltragenyx Pharmaceutical Inc
05/07/20244:30PMGlobeNewswire Inc.Ultragenyx to Participate at Bank of America’s 2024 Healthcare ConferenceNASDAQ:RAREUltragenyx Pharmaceutical Inc
05/02/20244:00PMGlobeNewswire Inc.Ultragenyx Reports First Quarter 2024 Financial Results and Corporate UpdateNASDAQ:RAREUltragenyx Pharmaceutical Inc
04/30/20244:00PMGlobeNewswire Inc.Ultragenyx Issues 2023 Corporate Responsibility Report, Showcasing Commitment to Improving Equity and Access to Innovation in Rare DiseaseNASDAQ:RAREUltragenyx Pharmaceutical Inc
04/30/20248:00AMGlobeNewswire Inc.Ultragenyx Announces Completion of Enrollment in Phase 3 Orbit and Cosmic Studies Evaluating Setrusumab (UX143) for the Treatment of Osteogenesis Imperfecta (OI)NASDAQ:RAREUltragenyx Pharmaceutical Inc
04/25/20244:30PMGlobeNewswire Inc.Ultragenyx to Host Conference Call for First Quarter 2024 Financial Results and Corporate UpdateNASDAQ:RAREUltragenyx Pharmaceutical Inc
04/19/20244:30PMGlobeNewswire Inc.Ultragenyx Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)NASDAQ:RAREUltragenyx Pharmaceutical Inc
 Showing the most relevant articles for your search:NASDAQ:RARE